Liquid Deprenyl Citrate
This article was originally published in The Tan Sheet
Discovery Experimental & Development, doing business as Astak, receives FDA warning letter Aug. 16 for claims Liquid Deprenyl Citrate is an effective treatment for diseases including depression, senile dementia, Parkinson's disease, Alzheimer's disease, ALS (Lou Gehrig's disease), high blood pressure, stroke induced paralysis and mental dysfunction. The product is classified by the agency as an unapproved new drug. The Wesley Chapel, Fla.-based firm did not follow the proper procedure when exporting the product to the U.K., FDA adds
You may also be interested in...
Perrigo promotes in pricing, planning
Combe sells most of its OTC brands
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC